KCTD8 Antikörper (AA 381-473) (Alexa Fluor 555)

Produktnummer ABIN1395083

Produktdetails anti-KCTD8 Antikörper (Alexa Fluor 555)

Target: KCTD8 (Potassium Channel Tetramerisation Domain Containing 8 (KCTD8))

Bindungsspezifität: AA 381-473

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser KCTD8 Antikörper ist konjugiert mit Alexa Fluor 555

Applikation: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Kreuzreaktivität: Human, Maus

Homologie: Rat,Dog,Cow,Sheep,Pig,Horse,Chicken,Rabbit

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human KCTD8

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu KCTD8

Target: KCTD8 (Potassium Channel Tetramerisation Domain Containing 8 (KCTD8))

Andere Bezeichnung: KCTD8 (KCTD8 Produkte)

Synonyme: A730087N02Rik antikoerper, potassium channel tetramerisation domain containing 8 antikoerper, potassium channel tetramerization domain containing 8 antikoerper, Kctd8 antikoerper, KCTD8 antikoerper

Hintergrund:

Synonyms: BTB/POZ domain-containing protein KCTD8, KCTD8, KCTD8_HUMAN, Potassium channel tetramerisation domain containing 8.

Background: Auxiliary subunit of GABA-B receptors that determine the pharmacology and kinetics of the receptor response. Increases agonist potency and markedly alter the G-protein signaling of the receptors by accelerating onset and promoting desensitization.

Pathways: Regulation of G-Protein Coupled Receptor Protein Signaling